Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E41.74 EPS (ttm)6.74 Insider Own0.40% Shs Outstand149.25M Perf Week-5.95%
Market Cap41.96B Forward P/E35.22 EPS next Y7.98 Insider Trans-4.94% Shs Float146.45M Perf Month-14.03%
Income1.00B PEG2.76 EPS next Q1.26 Inst Own95.20% Short Float2.33% Perf Quarter-10.73%
Sales3.54B P/S11.84 EPS this Y19.70% Inst Trans0.16% Short Ratio3.14 Perf Half Y-2.59%
Book/sh31.38 P/B8.96 EPS next Y15.94% ROA13.90% Target Price338.75 Perf Year-6.62%
Cash/sh22.87 P/C12.29 EPS next 5Y15.10% ROE23.10% 52W Range263.30 - 380.76 Perf YTD-15.26%
Dividend- P/FCF49.83 EPS past 5Y23.20% ROI15.80% 52W High-27.47% Beta1.14
Dividend %- Quick Ratio6.20 Sales past 5Y13.70% Gross Margin69.60% 52W Low4.88% ATR7.07
Employees7700 Current Ratio6.70 Sales Q/Q9.80% Oper. Margin29.30% RSI (14)27.67 Volatility2.27% 2.11%
OptionableYes Debt/Eq0.25 EPS Q/Q16.10% Profit Margin28.30% Rel Volume1.00 Prev Close281.12
ShortableYes LT Debt/Eq0.25 EarningsJan 29 AMC Payout0.00% Avg Volume1.09M Price276.16
Recom2.10 SMA20-7.45% SMA50-12.52% SMA200-11.38% Volume519,967 Change-1.76%
Jan-08-20Initiated Wells Fargo Underweight $300
Jan-07-20Initiated Citigroup Buy $385
Jan-02-20Downgrade Evercore ISI Outperform → In-line $330 → $340
Nov-15-19Initiated Stifel Buy
Oct-25-19Initiated Guggenheim Buy $350
Jul-30-19Downgrade Canaccord Genuity Buy → Hold $330 → $300
Jul-12-19Downgrade BofA/Merrill Buy → Underperform
May-30-19Initiated Wolfe Research Outperform
Jan-03-19Upgrade UBS Neutral → Buy
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Feb-25-20 07:46AM  Did You Miss Illumina's (NASDAQ:ILMN) 68% Share Price Gain? Simply Wall St.
Feb-20-20 04:41PM  Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD Zacks
Feb-19-20 02:03PM  The Top 5 Buys of Steve Mandel's Lone Pine Capital GuruFocus.com
Feb-17-20 05:44PM  Al Gore's Generation Investment Management Buys 4 Stocks in the 4th Quarter GuruFocus.com
Feb-12-20 04:22PM  Illumina to Webcast Upcoming Investor Conference Presentations Business Wire
Feb-07-20 07:33AM  Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4 Zacks
Feb-06-20 03:43PM  Valley startup scores $75M with an eye towards helping track coronavirus American City Business Journals
Feb-02-20 08:35AM  Illumina, Inc. Just Released Its Yearly Earnings: Here's What Analysts Think Simply Wall St.
Jan-31-20 10:08AM  Illumina, Inc. (NASDAQ:ILMN) Delivered A Better ROE Than Its Industry Simply Wall St.
Jan-30-20 05:45PM  Edited Transcript of ILMN earnings conference call or presentation 29-Jan-20 10:00pm GMT Thomson Reuters StreetEvents -5.52%
05:42PM  Mammoth Biosciences aims to be Illumina for the gene editing generation TechCrunch
04:07PM  US Stocks Choppy on Thursday GuruFocus.com
02:55PM  Coronavirus update: First U.S. case of person-to-person transmission confirmed, 195 U.S. citizens in isolation and WHO declares a public health emergency MarketWatch
12:36PM  Coronavirus: How Fast to 100,000 Infected? Zacks
11:11AM  Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand Zacks
Jan-29-20 05:45PM  Illumina (ILMN) Q4 Earnings and Revenues Top Estimates Zacks
05:00PM  DNA Testing Behemoth Illumina Slips As 2020 Outlook Comes Up Short Investor's Business Daily
04:11PM  Coronavirus: Epidemic or Pandemic? Zacks
04:05PM  Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019 Business Wire
11:10AM  Illumina Earnings, Revenue Beat in Q4 Investing.com
08:30AM  The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
Jan-27-20 05:21AM  Big Tech Gets Put on Guard by Antitrust Police Bloomberg
Jan-26-20 10:23AM  The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes Benzinga
Jan-24-20 08:48AM  Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings? Zacks
Jan-23-20 02:56PM  23andMe cuts 100 jobs as demand for DNA tests drops American City Business Journals
Jan-22-20 12:31PM  Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jan-15-20 05:50PM  4 High-Quality Health Care Companies for 2020 GuruFocus.com
Jan-13-20 04:05PM  Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020 Business Wire
03:37PM  Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook InvestorPlace
12:06PM  Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics Business Wire
11:55AM  Illumina and Roche Partner to Broaden Patient Access to Genomic Testing Business Wire
Jan-10-20 09:00AM  Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom Business Wire
08:00AM  ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests PR Newswire
Jan-08-20 11:40AM  EBS vs. ILMN: Which Stock Is the Better Value Option? Zacks
Jan-06-20 12:10PM  Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again Zacks
11:14AM  Illumina Stock Could Illuminate This Healthcare ETF ETF Trends
07:36AM  Why Illumina, Inc. (NASDAQ:ILMN) Could Be Worth Watching Simply Wall St.
Jan-03-20 03:34PM  Sequencing giant Illumina scraps $1.2 billion PacBio acquisition American City Business Journals
10:48AM  Illumina Stock Slips on Pacific Biosciences Deal Termination Zacks
10:18AM  Illumina and Pacific Biosciences Call the Merger Off. Shares Barely React. Barrons.com
07:55AM  The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger Benzinga
02:11AM  U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday TheStreet.com
01:20AM  U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday TheStreet.com
Jan-02-20 11:58PM  Illumina and Pacific Biosciences call off merger Financial Times
05:23PM  Illumina and Pacific Biosciences Call Off $1.2 Billion Deal Bloomberg
04:44PM  Illumina, Pacific Biosciences drop $1.2 billion merger agreement MarketWatch
04:05PM  Illumina and Pacific Biosciences Announce Termination of Merger Agreement Business Wire
Dec-30-19 08:31AM  Here's Why You Should Retain Pacific Biosciences Stock Now Zacks
Dec-27-19 03:02PM  Hedge Fund Favorites vs. Illumina, Inc. (ILMN) In 2019 Insider Monkey
Dec-23-19 05:42PM  Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
11:40AM  OSMT or ILMN: Which Is the Better Value Stock Right Now? Zacks
Dec-18-19 10:05AM  Pacific Biosciences stock falls on FTC challenge to Illumina deal MarketWatch
07:23AM  The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data Benzinga
Dec-17-19 05:57PM  Startup raises $55M to peer into proteins to tell us more about our ills American City Business Journals
Dec-11-19 07:35AM  We Think Illumina (NASDAQ:ILMN) Can Manage Its Debt With Ease Simply Wall St.
Dec-06-19 09:04AM  Genetic Testing Companies Take DNA Tests To A Whole New Level Investor's Business Daily
Dec-04-19 11:40AM  ALXN vs. ILMN: Which Stock Is the Better Value Option? Zacks
09:55AM  Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits Zacks
Dec-03-19 02:01PM  Hedge Funds Souring On Illumina, Inc. (ILMN) Insider Monkey
08:00AM  ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests PR Newswire
Nov-25-19 08:01AM  Here's Why You Should Hold on to Pacific Biosciences Stock Zacks
Nov-21-19 09:51AM  Capping 14-year quest, Peninsula company raises $90M to shrink DNA sequencing's size, cost American City Business Journals
Nov-20-19 04:05PM  Illumina to Webcast Upcoming Investor Conference Presentations Business Wire
07:14AM  Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates Zacks
Nov-19-19 12:03PM  Illumina set to train hundreds of employees at new Baltimore office American City Business Journals
Nov-18-19 11:09AM  Should You Be Tempted To Sell Illumina, Inc. (NASDAQ:ILMN) Because Of Its P/E Ratio? Simply Wall St.
Nov-13-19 09:30AM  EBS or ILMN: Which Is the Better Value Stock Right Now? Zacks
Nov-09-19 07:19PM  Cramer Weighs In On Nike, Beyond Meat And More Benzinga
Nov-08-19 09:00AM  Lexent Bio Enters Partnership with Illumina to Develop an In Vitro Diagnostic Kit PR Newswire
12:00AM  Investing in IPOs is an easy way to lose money Financial Times
Nov-04-19 05:40PM  Edited Transcript of ILMN earnings conference call or presentation 24-Oct-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-31-19 04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-28-19 03:26PM  Global Markets Advance Monday GuruFocus.com
09:15AM  S&P: 3 Weeks of Gains and 3 Points from a New Closing High Zacks
Oct-25-19 04:28PM  Consumer DNA Testing Hits The Skids And Takes Illumina Stock With It Investor's Business Daily -7.88%
03:10PM  Wall Street Jumps Friday GuruFocus.com
09:18AM  Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View Zacks
08:03AM  Dow Jones Futures: Amazon Dives On Earnings, But This Dow Giant Signals Breakout Investor's Business Daily
Oct-24-19 05:45PM  Illumina (ILMN) Q3 Earnings and Revenues Beat Estimates Zacks
05:40PM  Illumina Stock Dips As Consumer Genomics Weighs On Quarterly Beat Investor's Business Daily
04:21PM  Genomic Behemoth Illumina Crushes Third-Quarter Sales, Profit Forecasts Investor's Business Daily
04:05PM  Illumina Reports Financial Results for Third Quarter of Fiscal Year 2019 Business Wire
12:13PM  Illumina Earnings, Revenue Beat in Q3 Investing.com
09:44AM  Does Illumina, Inc.'s (NASDAQ:ILMN) CEO Pay Matter? Simply Wall St.
Oct-17-19 10:34AM  Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for Zacks
10:21AM  Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings? Zacks
Oct-16-19 05:38PM  Jerome Dodson's 3rd-Quarter New Buys GuruFocus.com
Oct-11-19 06:00AM  Illumina- Shining a Light on Gene Sequencing MoneyShow
Oct-10-19 08:42AM  QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits Zacks
Oct-09-19 08:26PM  Do Hedge Funds Love Illumina, Inc. (ILMN)? Insider Monkey
08:37AM  Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits Zacks
Oct-08-19 04:05PM  Illumina to Announce Third Quarter 2019 Financial Results on Thursday, October 24, 2019 Business Wire
03:16PM  Qiagens Results Are Hitting Health-Care Stocks. Heres What to Do Next. Barrons.com
09:45AM  Qiagen Shares Tumble Following Q3 Sales Warning, Sudden CEO Departure Benzinga
08:56AM  Qiagen Stock Plunges as CEO Departs, Sales Fall Short Barrons.com
07:11AM  The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration Benzinga
Oct-07-19 04:07PM  QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Business Wire
04:05PM  Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Business Wire
Oct-01-19 03:32PM  Does Illumina (NASDAQ:ILMN) Deserve A Spot On Your Watchlist? Simply Wall St.
11:56AM  Illumina, Broad Institute Partner on Secondary Genomic Analysis Zacks
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. It also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a collaboration with Roche to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology. The company operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, China, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 18Sale298.871,800537,95919,312Feb 20 05:04 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 11Option Exercise0.001,00104,742Feb 13 08:15 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 11Option Exercise0.0011,641030,166Feb 13 08:12 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 11Option Exercise0.009,969055,574Feb 13 08:10 PM
SAMAD SAMSVP and CFOFeb 11Option Exercise0.006,626014,407Feb 13 08:09 PM
Ronaghi MostafaSVP & CTOFeb 11Option Exercise0.0011,728094,732Feb 13 08:08 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 11Option Exercise0.009,969024,976Feb 13 08:06 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 11Option Exercise0.0013,488030,643Feb 13 08:05 PM
deSouza Francis APresident and CEOFeb 11Option Exercise0.0035,1840118,817Feb 13 07:39 PM
Dadswell CharlesSVP & General CounselFeb 11Option Exercise0.007,624016,943Feb 13 07:36 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 05Sale300.24625187,65010,623Feb 06 04:23 PM
SAMAD SAMSVP and CFOFeb 03Sale293.1023869,7583,011Feb 05 05:40 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 03Sale293.101,253367,2547,888Feb 05 05:37 PM
TOUSI SUSAN HSVP Product DevelopmentJan 06Sale325.0020065,00038,465Jan 08 04:10 PM
Van Oene MarkSVP Chief Commercial OfficerJan 02Sale330.99625206,86811,178Jan 06 04:12 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanDec 10Sale326.011,200391,2127,844Dec 12 05:13 PM
TOUSI SUSAN HSVP Product DevelopmentDec 06Sale325.001,000325,00038,665Dec 10 04:36 PM
Dadswell CharlesSVP & General CounselDec 02Sale320.33655209,8163,576Dec 04 07:25 PM
Van Oene MarkSVP Chief Commercial OfficerDec 02Sale320.15625200,09411,803Dec 04 07:19 PM
SAMAD SAMSVP and CFONov 29Sale320.00892285,4403,461Dec 03 08:35 PM
Febbo Phillip G.SVP Chief Medical OfficerNov 14Sale300.0015546,5001,506Nov 18 04:33 PM
RAGUSA ROBERT PSVP, Global Quality & OpsNov 01Sale297.281,674497,64710,192Nov 05 04:18 PM
Dadswell CharlesSVP & General CounselNov 01Sale297.2819357,3755,069Nov 05 04:55 PM
Van Oene MarkSVP Chief Commercial OfficerNov 01Sale300.10625187,56313,584Nov 05 04:50 PM
Ronaghi MostafaSVP & CTOOct 15Option Exercise69.344,000277,36080,585Oct 17 04:46 PM
Ronaghi MostafaSVP & CTOOct 15Sale310.934,0001,243,71176,585Oct 17 04:46 PM
Van Oene MarkSVP Chief Commercial OfficerOct 01Sale304.84625190,52514,209Oct 03 04:26 PM
Dadswell CharlesSVP & General CounselOct 01Sale304.2212437,7235,262Oct 03 04:24 PM
Ronaghi MostafaSVP & CTOSep 16Option Exercise69.3410,000693,40086,585Sep 18 05:03 PM
Ronaghi MostafaSVP & CTOSep 16Sale300.5310,0003,005,32376,585Sep 18 05:03 PM
Dadswell CharlesSVP & General CounselSep 03Sale279.881,220341,4545,386Sep 05 04:29 PM
FLATLEY JAY TDirectorAug 28Sale283.413,300935,253262,733Aug 29 04:33 PM
Ronaghi MostafaSVP & CTOAug 15Option Exercise69.3410,000693,40086,585Aug 19 04:50 PM
Ronaghi MostafaSVP & CTOAug 15Sale285.5210,0002,855,20376,585Aug 19 04:50 PM
FLATLEY JAY TDirectorAug 14Sale288.363,300951,588266,033Aug 15 06:31 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanAug 09Sale298.541,260376,16010,685Aug 13 04:10 PM
RAGUSA ROBERT PSVP, Global Quality & OpsAug 08Sale293.092,230653,59111,866Aug 12 05:22 PM
deSouza Francis APresident and CEOAug 01Sale301.253,000903,75961,600Aug 05 04:45 PM
Dadswell CharlesSVP & General CounselAug 01Sale300.0012437,2006,606Aug 05 04:40 PM
FLATLEY JAY TDirectorJul 24Sale304.003,3001,003,200269,316Jul 25 05:22 PM
Ronaghi MostafaSVP & CTOJul 15Option Exercise69.3410,000693,40086,776Jul 18 11:38 AM
Ronaghi MostafaSVP & CTOJul 15Sale302.0410,0003,020,39276,776Jul 18 11:38 AM
FLATLEY JAY TDirectorJul 10Sale376.503,3001,242,450272,616Jul 12 06:19 PM
deSouza Francis APresident and CEOJul 01Sale369.553,0001,108,65564,936Jul 03 04:50 PM
Dadswell CharlesSVP & General CounselJul 01Sale371.2912446,0406,679Jul 03 04:47 PM
FLATLEY JAY TDirectorJun 26Sale358.153,3001,181,895275,916Jun 28 04:06 PM
Ronaghi MostafaSVP & CTOJun 17Option Exercise69.3410,000693,40086,776Jun 19 07:07 PM
Ronaghi MostafaSVP & CTOJun 17Sale349.2810,0003,492,75376,776Jun 19 07:07 PM
FLATLEY JAY TDirectorJun 12Sale334.533,3001,103,949279,216Jun 14 04:00 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanJun 10Sale335.031,260422,13811,945Jun 12 04:05 PM
deSouza Francis APresident and CEOJun 03Sale309.693,000929,08067,936Jun 05 04:34 PM
Dadswell CharlesSVP & General CounselJun 03Sale309.701,220377,8386,866Jun 05 04:27 PM
FLATLEY JAY TDirectorMay 22Sale304.443,3001,004,652282,516May 24 05:22 PM
Ronaghi MostafaSVP & CTOMay 15Option Exercise69.3410,000693,40087,414May 16 08:34 PM
Ronaghi MostafaSVP & CTOMay 15Sale305.4910,0003,054,87677,414May 16 08:34 PM
ARNOLD FRANCESDirectorMay 13Sale307.951,503462,84910,159May 15 04:44 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanMay 10Sale315.321,260397,30313,205May 13 07:42 PM
FLATLEY JAY TDirectorMay 08Sale318.593,3001,051,347285,816May 10 05:50 PM
EPSTEIN ROBERT SDirectorMay 01Option Exercise51.175,000255,8508,256May 03 05:18 PM
EPSTEIN ROBERT SDirectorMay 01Sale310.445,0001,552,1783,256May 03 05:18 PM
deSouza Francis APresident and CEOMay 01Sale310.013,000930,02970,936May 03 05:12 PM
Dadswell CharlesSVP & General CounselMay 01Sale311.7712438,6598,086May 03 05:07 PM
FLATLEY JAY TDirectorApr 24Sale321.963,3001,062,468289,116Apr 26 05:29 PM
FLATLEY JAY TDirectorApr 10Sale317.013,3001,046,133331,668Apr 12 04:33 PM
EPSTEIN ROBERT SDirectorApr 01Option Exercise51.171,00051,1704,256Apr 03 05:28 PM
EPSTEIN ROBERT SDirectorApr 01Sale314.451,000314,4503,256Apr 03 05:28 PM
deSouza Francis APresident and CEOApr 01Sale315.933,000947,78873,746Apr 03 05:25 PM
Dadswell CharlesSVP & General CounselApr 01Sale314.4512438,9928,210Apr 03 05:22 PM
FLATLEY JAY TDirectorMar 27Sale306.933,3001,012,869334,968Mar 29 04:01 PM
FLATLEY JAY TDirectorMar 13Sale306.503,3001,011,450338,268Mar 29 04:01 PM
EPSTEIN ROBERT SDirectorMar 01Option Exercise51.171,00051,1704,256Mar 05 04:57 PM
EPSTEIN ROBERT SDirectorMar 01Sale313.931,000313,9303,256Mar 05 04:57 PM
deSouza Francis APresident and CEOMar 01Sale316.513,000949,51876,746Mar 05 04:58 PM
Dadswell CharlesSVP & General CounselMar 01Sale313.931,220382,9958,334Mar 05 04:56 PM
FLATLEY JAY TDirectorFeb 27Sale300.003,300990,000341,568Mar 01 05:23 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 26Sale304.6329890,7802,297Feb 28 05:30 PM